Lu at al. [1] observed an increased AAb response to p53, HER-2, MUC1, topoisomerase II alpha (TOPO2α), insulin-like growth factor binding protein 2 (IGFBP2), cyclin D1, and Cathepsin D in breast carcinoma patients. This evidence concerns the gene CCND1 and breast carcinoma.